Pfizer (PFE) Completes Acquisition of Seagen (SGEN)

Go back to Pfizer (PFE) Completes Acquisition of Seagen (SGEN)

Pfizer Completes Acquisition of Seagen

December 14, 2023 7:39 AM EST

Further establishes Pfizer as a leading oncology company poised to accelerate the next generation of breakthrough treatments for people with cancer To address U.S. Federal Trade Commission concerns, Pfizer has chosen to irrevocably donate the rights of royalties from sales of Bavencio® (avelumab) in the U.S. to the American Association for Cancer Research (AACR)

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Seagen Inc. (NASDAQ: SGEN), a global biotechnology company that... More